source
- Clinical trial enrollment crisis threatens billions in revenue and patient accessClinical trials are struggling with enrollment, with about 80% missing timelines and less than 5% of eligible adult cancer patients participating. Delays have huge financial impact; each day a pha…
- Orbis Medicines signs up to $1.4 billion partnership with Novo to develop macrocycle drugs for cardiometabolic diseaseOrbis Medicines, which is backed by Eli Lilly, announced a new collaboration with Novo focused on drug discovery. The agreement, valued at up to $1.4 billion, will target the creation of macrocycl…